Clinical Trial Update: Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan

View source ↗

Summary

A completed clinical trial in Taiwan evaluated changes in psoriasis disease state after subcutaneous risankizumab in adults. The study was sponsored by AbbVie.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• SKYRIZI (risankizumab-rzaa)

Snippet

Sponsor: AbbVie | Conditions: Psoriasis | Status: COMPLETED